Issue 67, 2020, Issue in Progress

Molecular engineering of the last-generation CNTs in smart cancer therapy by grafting PEG–PLGA–riboflavin

Abstract

In this work, the effect of environment and additives on the self-assembly and delivery of doxorubicin (DOX) have been studied. A microfluidic system with better control over molecular interactions and high surface to volume ratio has superior performance in comparison to the bulk system. Moreover, carbon nanotube (CNT) and CNT-doped structures have a high surface area to incorporate the DOX molecules into a polymer and the presence of functional groups can influence the polymer–drug interactions. In this work, the interactions of DOX with both the polymeric complex and the nanotube structure have been investigated. For quantification of the interactions, H-bonding, gyration radius, root-mean-square deviation (RMSD), Gibbs free energy, radial distribution function (RDF), energy, and Solvent Accessible Surface Area (SASA) analyses have been performed. The most stable micelle–DOX interaction is attributed to the presence of BCN in the microfluidic system according to the gyration radius and RMSD. Meanwhile, for DOX-doped CNT interaction the phosphorus-doped CNT in the microfluidic system is more stable. The highest electrostatic interaction can be seen between polymeric micelles and DOX in the presence of BCN. For nanotube–drug interaction, phosphorus-doped carbon nanotubes in the microfluidic system have the largest electrostatic interaction with the DOX. RDF results show that in the microfluidic system, nanotube–DOX affinity is larger than that of nanotube–micelle.

Graphical abstract: Molecular engineering of the last-generation CNTs in smart cancer therapy by grafting PEG–PLGA–riboflavin

Supplementary files

Article information

Article type
Paper
Submitted
01 Sep 2020
Accepted
23 Oct 2020
First published
09 Nov 2020
This article is Open Access
Creative Commons BY license

RSC Adv., 2020,10, 40637-40648

Molecular engineering of the last-generation CNTs in smart cancer therapy by grafting PEG–PLGA–riboflavin

S. Sohrabi, M. Khedri, R. Maleki and M. Keshavarz Moraveji, RSC Adv., 2020, 10, 40637 DOI: 10.1039/D0RA07500K

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements